pc 버전으로 이동 중 [시장보고서]두경부 편평상피암용 세포치료 : 파이프라인 분석(2024년)
두경부 편평상피암용 세포치료 : 파이프라인 분석(2024년)
Cell Therapies in Head and Neck Squamous Cell Carcinoma - Pipeline Analytics 2024
상품코드 : 1474029
리서치사 : Mellalta Meets LLP
발행일 : 2024년 05월
페이지 정보 : 영문 109 Pages
 라이선스 & 가격 (부가세 별도)
US $ 2,500 ₩ 3,463,000
PPT (Single User License)
US $ 3,500 ₩ 4,848,000
PPT (2 - 3 User License)
US $ 5,000 ₩ 6,926,000
PPT (Site License - Up to 10 Users)
US $ 7,500 ₩ 10,389,000
PPT (Enterprise License)


한글목차

ACT(Adoptive cell therapies)는 다양한 암의 초기 단계 시험에서 유망한 결과를 보여주고 있습니다. 그러나 두경부 편평상피암(HNSCC) 치료에서 성공적인 접근법은 고형암에 공통적으로 나타나는 고유한 과제에 직면해 있습니다. 이러한 과제에는 T세포가 종양을 효과적으로 표적화할 수 있는 적절한 호밍 메커니즘을 확립하고, 강력한 면역반응을 위해 종양 내로 충분한 T세포 침윤을 확보하며, 종양 외부에 영향을 미치지 않는 항원을 식별하는 것 등이 포함됩니다. 하지만 가까운 미래에 치료에서 중요한 역할을 할 것이라는 낙관적인 전망도 있습니다. 이는 화학요법에 불응하는 환자를 위한 체크포인트 억제제와의 병용요법이나 재발성 전이의 1차 치료에서 가능성이 있습니다.

분석에 따르면 개발 파이프라인에는 TCR T세포 치료, 종양침윤림프구(TILs), 면역관문억제제(ICI)와의 병용요법 등 HNSCC 치료에 도움이 될 수 있는 다양한 세포치료제가 있습니다.

두경부 편평상피암용 세포치료에 대해 조사했으며, 시장 기회, 주요 경쟁 분석, 기업의 파이프라인 의약품 개요, 임상시험, 기타 발전 동향 등을 정리하여 전해드립니다.

목차

제1장 리포트의 개요

제2장 두경부 편평상피암(HNSCC)용 세포치료 표적의 배경

제3장 두경부 편평상피암(HNSCC)용 세포치료 파이프라인 분석

제4장 임상시험과 연구

제5장 라이선싱, 취득, 협업

제6장 파이프라인 상황

제7장 HNSCC용 세포치료 SWOT 분석

제8장 부록

KSA 24.05.14
영문 목차

영문목차

The Cell Therapies in Head and Neck Squamous Cell Carcinoma - Pipeline Analytics -2024 report published by Mellalta Meets covers the Cell Therapies market opportunity providing Key Competitive Analysis, 17+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports cover pipeline product analysis by stage of development, competitive landscape by phases, companies, clinical trials by regions, cell therapy modalities, and intervention type. Cell Therapies in Head and Neck Squamous Cell Carcinoma-Pipeline Analytics report adds value in terms of describing clinical-stage products for their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers, and challenges.

Adoptive cell therapies (ACT) have demonstrated promising outcomes in early-stage trials across various cancers. However, successful approaches in treating HNSCC face specific challenges commonly found in solid tumors. These challenges include the necessity to establish appropriate homing mechanisms for T cells to effectively target the tumor, ensuring adequate T-cell infiltration into the tumor for a robust immune response, and identifying antigens that will not lead to off-tumor effects. While ACT approaches are still in their early stages for HNSCC, there is optimism that they will soon play a significant role in treatment. This may involve potential combinations with checkpoint inhibitors for patients with chemotherapy-refractory disease and potentially in the first-line recurrent metastatic setting.

In this report, Mellalta Meets provides an in-depth analysis of the Cell Therapies in the HNSCC Pipeline covering preclinical and clinical studies, details of partnerships and business deal values, targeted technologies and therapy areas, investments, and acquisition trends. Currently, there are more than 17 candidates in the Cell Therapies in the HNSCC Pipeline under evaluation in clinical and preclinical studies. The major key players operating in the market are Iovance Biotherapeutics, ImmunityBio, Rapa Therapeutics, TCRCure Biopharma, Immatics, and many more which have a robust clinical pipeline of cell therapy candidates for HNSCC.

As per analysis, the development pipeline is full of different cell therapy modalities like TCR T-cell therapies, tumor-infiltrating lymphocytes (TILs), and combination approaches with immune checkpoint inhibitors (ICI) which can help in addressing HNSCC.

Mellalta's HER2-Low Breast Cancer Pipeline Report - Key Highlights

There are 5 products in the Phase 2 and Phase 1/2 stage of development, representing 15% of the total share of the developing Cell Therapies in HNSCC.

The HNSCC cell therapies landscape is dominated by Phase 1 stage assets accounting for 54.55% followed by Discovery stage products which account for 24.24%.

To be continued...

Report Coverage:

Indication Prioritization: HNSCC market potential

Business Transactions & Strategies: Key collaborations and deal values

HNSCC Cell Therapies Pipeline Development: Product Profiles, Clinical Trials & Results

HNSCC Cell Therapies Acquisition Targets

HNSCC Cell Therapies Competitive Intelligence

Recent and upcoming events

Table of Content

1.Report Overview

2.The Cell Therapies in HNSCC Target Background

3.Cell Therapies in HNSCC Pipeline Analysis

4.Clinical Trials and Research

5.Licensing, Acquisition, and Collaboration

6.Pipeline Landscape

7.Cell Therapies in HNSCC SWOT Analysis

8.Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기